MARKET

FUSN

FUSN

Fusion Pharmaceuticals Inc.
NASDAQ
21.40
-0.02
-0.09%
After Hours: 21.40 0 0.00% 16:20 04/24 EDT
OPEN
21.43
PREV CLOSE
21.42
HIGH
21.44
LOW
21.34
VOLUME
273.01K
TURNOVER
0
52 WEEK HIGH
21.55
52 WEEK LOW
2.310
MARKET CAP
1.82B
P/E (TTM)
-14.7964
1D
5D
1M
3M
1Y
5Y
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
NASDAQ · 1d ago
Weekly Report: what happened at FUSN last week (0415-0419)?
Weekly Report · 2d ago
Fusion Pharmaceuticals Cut to Hold From Buy by TD Cowen
Dow Jones · 04/16 12:03
TD Cowen Downgrades Fusion Pharmaceuticals to Hold
Benzinga · 04/16 11:52
FUSION PHARMACEUTICALS INC <FUSN.O>: TD COWEN CUTS TO HOLD FROM BUY
Reuters · 04/16 05:53
Weekly Report: what happened at FUSN last week (0408-0412)?
Weekly Report · 04/15 09:25
Fusion Pharmaceuticals: Market Perform Rating Amid Acquisition and Promising Prostate Cancer Treatment Data
TipRanks · 04/12 05:37
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
NASDAQ · 04/11 21:50
More
About FUSN
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Webull offers Fusion Pharmaceuticals Inc stock information, including NASDAQ: FUSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FUSN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FUSN stock methods without spending real money on the virtual paper trading platform.